The Food and Drug Administration (FDA) has approved Arbliâ„¢, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor ...
The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results